# A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy

> **NCT01693822** · PHASE2 · COMPLETED · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 65 (actual)

## Conditions studied

- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT01693822
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2017-03
- **Final completion:** 2022-02-28
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693822, "A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01693822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*